Prexa Pharmaceuticals is a Boston-based biotechnology company focused on therapies for central nervous system diseases and disorders. It is developing oral small-molecule monoamine reuptake inhibitors intended to improve the safety and efficacy of current treatments for ADHD, depression and Parkinson’s disease. The company’s lead product candidate is PRX-12251. Prexa plans to use the newly raised funds to complete IND-enabling studies for PRX-12251. Its product pipeline includes mono and dual reuptake inhibitors targeted for partnerships with biotechnology and pharmaceutical companies. Founded in 2006, the company is led by Chairman and CEO Charles Cohen, Ph.D.

Total raised

$7M

Funding rounds

1

Latest round

Series B

Latest activity

May 2011